A study to investigate INM 750 for the treatment of epidermolysis bullosa simplex

Trial Profile

A study to investigate INM 750 for the treatment of epidermolysis bullosa simplex

Planning
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs INM 750 (Primary)
  • Indications Epidermolysis bullosa
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 04 Nov 2015 According to an InMed media release, this study is expected to be completed by the end of 2016.
    • 08 Aug 2015 New trial record
    • 06 Aug 2015 InMed anticipates commencing human proof of concept clinical studies of INM-750 in February 2016 with initial data expected by Q3 2016 after which InMed will seek orphan drug designation for INM-750 with the US FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top